Molecular basis includes TP53 described in patients who had an aggressive clinical course and other mutations characteristic for other skin cancers, such as TOP1 (DNA topoisomerase I), NF1 (neurofibromin 1), or NRAS (Table 1) [11,14]. This evidence concerns the gene TOP1 and skin cancer.